div class=ts-pagebutton class=gotoPage data-page=1Page 1button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=1 data-page=1 class=ts-thumb lazyload alt=Page 1: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails1jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=2Page 2button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=2 data-page=2 class=ts-thumb lazyload alt=Page 2: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails2jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=3Page 3button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=3 data-page=3 class=ts-thumb lazyload alt=Page 3: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails3jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=4Page 4button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=4 data-page=4 class=ts-thumb lazyload alt=Page 4: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails4jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=5Page 5button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=5 data-page=5 class=ts-thumb lazyload alt=Page 5: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails5jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=6Page 6button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=6 data-page=6 class=ts-thumb lazyload alt=Page 6: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails6jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=7Page 7button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=7 data-page=7 class=ts-thumb lazyload alt=Page 7: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails7jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=8Page 8button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=8 data-page=8 class=ts-thumb lazyload alt=Page 8: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails8jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=9Page 9button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=9 data-page=9 class=ts-thumb lazyload alt=Page 9: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails9jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=10Page 10button div class=ts-imageimg data-url=astrazeneca-tax-transp-astrazeneca-had-a-net-accounting-add-back-of-a6699828htmlpage=10 data-page=10 class=ts-thumb lazyload alt=Page 10: AstraZeneca Tax Transp… · AstraZeneca had a net accounting add-back of A$6699828 which predominantly relates to the following 1 Research and Development RD expenses: RD loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader033vdocumentssitereader033viewer20220502025f56279b26ba3b5dc40a4626html5thumbnails10jpg width=140 height=200 divdiv
